Covid 19 Research using Clinical Trials (Home Page)
Biological: COVID-19 convalescent plasmaWiki
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (1)
|
Name (Synonyms) |
Correlation |
drug2550 | Transcranial direct current stimulation (tDCS) Soterix Medical Inc. tDCS unit Wiki | 0.71 |
Correlated MeSH Terms (2)
|
Name (Synonyms) |
Correlation |
D000544 | Alzheimer Disease NIH | 0.58 |
D060825 | Cognitive Dysfunction NIH | 0.35 |
There is one clinical trial.
Clinical Trials
I. Study Design: This is a single-arm feasibility study to assess the safety and efficacy of
anti-SARS-CoV-2 convalescent plasma (CP) in
1. intubated, mechanically ventilated patients with confirmed COVID-19 pneumonia by chest
X-ray or chest CT.
2. hospitalized patients with acute respiratory symptoms between 3 and 7 days after the
onset of symptoms, with COVID-19.
II. Study Population:
1. Population 1: Mechanically ventilated intubated COVID-19 patients aged 18 years or
older.
2. Population 2: Hospitalized COVID-19 patients aged ≥18 years of age with respiratory
symptoms within 3 to 7 days from the beginning of illness.
III. Study Agent:
SARS-CoV-2 convalescent plasma (1-2 units; ~200-400 mL at neutralization antibody titer
>1:160.
NCT04358211 COVID-19 Biological: Biological: COVID-19 convalescent plasma
No related HPO nodes (Using clinical trials)